131 related articles for article (PubMed ID: 32983965)
1. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
Booth L; West C; Hoff DV; Dent P
Front Oncol; 2020; 10():1331. PubMed ID: 32983965
[TBL] [Abstract][Full Text] [Related]
2. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
Booth L; West C; Moore RP; Hoff DV; Dent P
Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
[TBL] [Abstract][Full Text] [Related]
3. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
[TBL] [Abstract][Full Text] [Related]
4. GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
Booth MR; Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Feb; 15():124-133. PubMed ID: 38329728
[TBL] [Abstract][Full Text] [Related]
5. GZ17-6.02 kills PDX isolates of uveal melanoma.
Booth L; Roberts JL; Spasojevic I; Baker KC; Poklepovic A; West C; Kirkwood JM; Dent P
Oncotarget; 2024 May; 15():328-344. PubMed ID: 38758815
[TBL] [Abstract][Full Text] [Related]
6. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Front Oncol; 2021; 11():711043. PubMed ID: 34490108
[TBL] [Abstract][Full Text] [Related]
7. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.
Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Mar; 15():159-174. PubMed ID: 38441437
[TBL] [Abstract][Full Text] [Related]
8. GZ17-6.02 kills prostate cancer cells
Booth L; Roberts JL; West C; Dent P
Front Oncol; 2022; 12():1045459. PubMed ID: 36408163
[TBL] [Abstract][Full Text] [Related]
9. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
Booth L; West C; Von Hoff D; Kirkwood JM; Dent P
Front Oncol; 2021; 11():656453. PubMed ID: 33898322
[TBL] [Abstract][Full Text] [Related]
10. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
11. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
12. Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells.
Roberts JL; Booth L; Poklepovic A; Dent P
Front Oncol; 2021; 11():723966. PubMed ID: 34604061
[TBL] [Abstract][Full Text] [Related]
13. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
14. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod Augments Monomethylfumarate Killing of GBM Cells.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
Front Oncol; 2020; 10():22. PubMed ID: 32047722
[TBL] [Abstract][Full Text] [Related]
16. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
17. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
Booth L; Roberts JL; West C; Von Hoff D; Dent P
J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of autophagy and cell viability by ceramide species.
Cruickshanks N; Roberts JL; Bareford MD; Tavallai M; Poklepovic A; Booth L; Spiegel S; Dent P
Cancer Biol Ther; 2015; 16(5):733-42. PubMed ID: 25803131
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
[TBL] [Abstract][Full Text] [Related]
20. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
